Peter Gorman is a Neurology physician affiliated with University of Maryland, Baltimore. OpenAlex indexes 84 publications with 2,074 citations (h-index 22); ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingClinical trials
- Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma
Sponsor: Cancer Trials Ireland
- Evaluation of Splinting in Tetraplegia
Sponsor: Thomas Jefferson University
- Study of the Efficacy and Safety of RsqVD Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma
Sponsor: Cancer Trials Ireland
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
63.3%Opioid Agonist29%Oxycodone Hcl34%Tramadol Hcl13%Fentanyl12%Morphine Sulfate Er12%Methadone Hcl10%Morphine Sulfate8%Oxycontin6%Hydromorphone Hcl5%Part D<11 patientsGabapentinoids19%Gabapentin81%Pregabalin19%Part D<11 patients+ 4 more classes in this area
Musculoskeletal
23.8%gamma-Aminobutyric Acid-ergic Agonist20.8%Baclofen100%Part D≥38 patientsCentral alpha-2 Adrenergic Agonist3%Tizanidine Hcl100%Part D<11 patientsGenitourinary & hormones
7.3%Cholinergic Muscarinic Antagonist4.4%Oxybutynin Chloride Er66%Oxybutynin Chloride34%Part D<11 patientsbeta3-Adrenergic Agonist1.5%Myrbetriq100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2004–2007 per NIH RePORTER. The latest:
- A BLINDED CONTROLLED STUDY OF ALENDRONATE IN CHRONIC SPINAL CORD INJURY
University of Maryland Baltimore
FY2007$881M01RR016500 - A BLINDED CONTROLLED STUDY OF ALENDRONATE IN CHRONIC SPINAL CORD INJURY
University of Maryland Baltimore
FY2006$10,398M01RR016500 - A BLINDED CONTROLLED STUDY IN ALENDRONATE IN CHRONIC SCL
University of Maryland Baltimore
FY2005$20,316M01RR016500
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Steven Kittner
University of Maryland, Baltimore
Edward Sausville, MD
University of Maryland, Baltimore
Aloke Finn, MD
University of Maryland, Baltimore
Christopher Plowe, MD
University of Maryland, Baltimore
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”